scholarly journals An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens

2006 ◽  
Vol 60 (12) ◽  
pp. 1300-1306 ◽  
Author(s):  
E A Rakha ◽  
I O Ellis
Keyword(s):  
Breast Cancer ◽  
Predictive Factors ◽  
Core Biopsy ◽  
Needle Core Biopsy ◽  
Biopsy Specimens ◽  
Prognostic And Predictive Factors

SP3, a reliable alternative to HercepTest in determining HER-2/neu status in breast cancer patients

2013 ◽  
Vol 66 (5) ◽  
pp. 409-414 ◽  
Author(s):  
Timothy Michael D'Alfonso ◽  
Yi-Fang Liu ◽  
Zhengming Chen ◽  
Ying-Bei Chen ◽  
Ashley Cimino-Mathews ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Core Biopsy ◽  
In Situ Hybridisation ◽  
Excisional Biopsy ◽  
Needle Core Biopsy ◽  
Breast Cancer Patients ◽  
Biopsy Specimens ◽  
Her 2

Accurate assessment of HER-2/neu gene status in breast cancer patients has important prognostic and therapeutic implications. Overexpression/gene amplification of HER-2 is associated with a more aggressive clinical course and eligibility for targeted therapy with trastuzumab. A variety of immunohistochemical (IHC) antibodies and in situ hybridisation (ISH) methods have been employed to assess HER-2 status. SP3 is a rabbit monoclonal antibody that has been shown to have a high level of agreement with other anti-HER-2 antibodies and ISH methods. We assessed HER-2 status by SP3 and HercepTest IHC stains and by fluorescence in situ hybridisation (FISH) on invasive breast carcinomas from paired needle core biopsy and excisional biopsy specimens from 100 patients. We compared the two antibodies with respect to concordance rates with FISH, concordance rates between samples of the same tumour, and sensitivity and specificity using FISH as the reference test. Concordance between SP3 and FISH in needle core biopsy and excisional biopsy specimens was 96% (95% CI 91.9% to 99.7%) (κ=0.89 (95% CI 0.73 to 1.00)) and 97% (95% CI 90.3% to 99.3%) (κ=0.84 (95% CI 0.66 to 1.00)), respectively. Sensitivity and specificity of SP3 for detecting HER-2 overexpression/gene amplification were 78.3% and 100%, respectively, in needle core biopsy and excisional biopsy specimens. Concordance between SP3 results assessed on the needle core biopsy and excisional biopsy was 89% (95% CI 81.2% to 94.4%) (κ=0.62 (95% CI 0.42 to 0.82)). Concordance between SP3 and HercepTest antibodies, after excluding 2+ cases, was 97.6% (95% CI 94.0% to 99.3%) (κ=0.88 (95% CI 0.77 to 1.00)). SP3 is a reliable alternative to HercepTest in evaluating HER-2 status in breast cancer patients. Like other anti-HER-2 antibodies, SP3 may serve as a diagnostic tool in breast pathology and has potential utility as an IHC biomarker in non-mammary malignancies.

scholarly journals Molecular characterization of breast cancer needle core biopsy specimens by the 21‐gene Breast Recurrence Score test

2020 ◽  
Vol 122 (4) ◽  
pp. 611-618 ◽  
Author(s):  
Debbie M. Jakubowski ◽  
Helen Bailey ◽  
John Abran ◽  
Andrea Blacklock ◽  
Nancy Ciau ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Molecular Characterization ◽  
Core Biopsy ◽  
Score Test ◽  
Recurrence Score ◽  
Needle Core Biopsy ◽  
Biopsy Specimens ◽  
Breast Recurrence

Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens

2016 ◽  
Vol 40 (8) ◽  
pp. 1090-1099 ◽  
Author(s):  
Christopher J. VandenBussche ◽  
Ashley Cimino-Mathews ◽  
Ben Ho Park ◽  
Leisha A. Emens ◽  
Theodore N. Tsangaris ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Ductal Carcinoma In Situ ◽  
Core Biopsy ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Needle Core Biopsy ◽  
Biopsy Specimens

Prognostic and predictive factors and genetic analysis of early breast cancer

2009 ◽  
Vol 11 (10) ◽  
pp. 634-642 ◽  
Author(s):  
Miguel Martín ◽  
Fernando González Palacios ◽  
Javier Cortés ◽  
Juan de la Haba ◽  
José Schneider
Keyword(s):  
Breast Cancer ◽  
Genetic Analysis ◽  
Early Breast Cancer ◽  
Predictive Factors ◽  
Prognostic And Predictive Factors

Prognostic and Predictive Factors, Treatment and Clinical Behavior of Palpable versus Nonpalpable Breast Cancer

2009 ◽  
Vol 15 (6) ◽  
pp. 668-670
Author(s):  
Ana Sofia Custódio ◽  
Sandra Lemos ◽  
Sofia Saleiro ◽  
Joana Migueis ◽  
Margarida Dias ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Predictive Factors ◽  
Clinical Behavior ◽  
Nonpalpable Breast Cancer ◽  
Prognostic And Predictive Factors

Patterns of HER2/neu, hormonal receptor expression, and proliferative activity in primary and metastatic breast cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 1071-1071
Author(s):  
F. Giotta ◽  
G. Simone ◽  
V. Fazio ◽  
S. Longo ◽  
S. Petroni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Predictive Factors ◽  
Proliferative Activity ◽  
Metastatic Breast ◽  
Receptor Expression ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Prognostic And Predictive Factors ◽  
Mib 1

1071 Background: The modification of biological features of metastatic sites (MS) in breast cancer patients arise some debatable questions regarding clinically usefull information and safe/efficient methods to detect them. Fine needle aspiration (FNA) of visceral MS is an available tool to characterize tumoral lesion and liquid based citology technique provides usefull cell samples for immunocytochemical and/or molecular assays. Methods: The aim of this study was to compare prognostic and predictive factors obtained from primary tumors (PT) and corresponding MS. Fluorescent in situ hybridization (FISH) was performed for HER2/Neu determination, while ER, PgR, and MIB-1 were detected by immunochemistry using specific monoclonal antibodies on monolayered cell sample and in the corresponding cytoinclusion. FNA with a 21–23 G needle was performed in 20 consecutive breast cancer patients with distant metacronous MS. Results: In 8/20 patients, both ER and PgR were absent in PT and in MS, in 7 were both present, in 4 cases only ER was detected, and only 1 case was ER negative with a low PgR. About the proliferative activity (MIB-1 index: cut off value >20%) only 3 MS presented an higher value. With regard to HER2/Neu, 4/20 cases were amplified and no discrepancies were found between cytological and cytoinclusion specimens. No substantial changes were found about kinetic activity. HER2/Neu status as assessed in PT was confirmed in MS in 10/12 cases; a lung mestastasis showed amplification while primary was not amplified and a liver lesion lost the amplification which was detected in the PT. Conclusions: Our study strongly suggest the opportunity in using FNA for detection of prognostic and predictive factors in MS. Pectasides et al. (Anticancer Res. 2006) found in patients with altered or conserved HER2/Neu in PT and in MS different response rates between the two groups and a significant poorer prognosis in patients with altered Neu. We think that liquid-based cytology applied on FNA of distant metastases could help us to understand some more in this issue. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document